Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
PHASE2CompletedINTERVENTIONAL
Enrollment
70
Participants
Timeline
Start Date
September 30, 2015
Primary Completion Date
March 16, 2022
Study Completion Date
March 16, 2022
Conditions
Hodgkin Lymphoma
Interventions
DRUG
B-CAP
DRUG
Brentuximab Vedotin
Trial Locations (1)
50924
1st Dept. of Medicine, Cologne University Hospital, Cologne
All Listed Sponsors
lead
University of Cologne
OTHER
NCT02191930 - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter